Search hospitals > Kansas > Overland Park
University of Kansas Cancer Center-Overland Park
Claim this profileOverland Park, Kansas 66210
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Prostate Cancer
220 reported clinical trials
31 medical researchers
Summary
University of Kansas Cancer Center-Overland Park is a medical facility located in Overland Park, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Prostate Cancer and other specialties. University of Kansas Cancer Center-Overland Park is involved with conducting 220 clinical trials across 408 conditions. There are 31 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Jun ZhangHouston Methodist Hospital4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
25 reported clinical trials
40 drugs studied
Gary C. DoolittleHaysMed University of Kansas Health System3 years of reported clinical research
Studies Cancer
Studies Melanoma
18 reported clinical trials
29 drugs studied
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
19 reported clinical trials
31 drugs studied
Andrea D. JewellUniversity of Kansas Cancer Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
16 reported clinical trials
38 drugs studied
Clinical Trials running at University of Kansas Cancer Center-Overland Park
Breast Cancer
Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lung Cancer
Tumors
Bladder Cancer
Pancreatic Cancer
Lymphoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Kansas Cancer Center-Overland Park?
University of Kansas Cancer Center-Overland Park is a medical facility located in Overland Park, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Prostate Cancer and other specialties. University of Kansas Cancer Center-Overland Park is involved with conducting 220 clinical trials across 408 conditions. There are 31 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.